2018 Section 5 - Rhinology and Allergic Disorders

DURHAM AND PENAGOS

J ALLERGY CLIN IMMUNOL February 2016

Dropout rate

8%

Medication scores

AIT , Allergen immunotherapy; AU , allergy units; AUC , area under the curve; DBPC , double-blind, placebo-controlled; ID , intradermal; NA , not available; NAC , nasal allergen challenge; NF , nasal fluid; SAR , seasonal allergic rhinitis; SMS , symptoms and medication scores; SPT , skin prick test; SQ-U , standardized quality units; TAME , N-alpha-tosyl-L-arginine methyl ester.

Included in previous

column

reduction in SMS compared with baseline ( P 5 .004).

in year 1 compared with placebo ( P 5 .02). After

( P 5 .01), and this remained

7 3 4 0 The active group had significant

reductions in SMS

switching to the

active treatment, participants previously

receiving placebo also showed a significant

Patients receiving active SCIT reported a

subjective

improvement

assessed by an

analogue scale from year 1

unchanged up to

4 years after the

discontinuation of

AIT. Participants

receiving initially

placebo improved

after switching to

active SCIT, and

this was maintained 4 years after AIT discontinuation.

blinded after

Years

cessation Symptom scores

after

Years

cessation

therapy

Immuno-

duration (y)

duration (y)

Total

study

Cumulative dose

100,000–120,000 AUeq

Subsequent years: 120,000 AUeq

Study methods and immunotherapy schedule Units

AU Year 1:

Maintenance phase: Frequency : Monthly Dose : 10,000 AUeq Duration : (DBPC phase) 1 year 1 (open

after AIT cessation. Build-up phase: Frequency : Weekly

4,000, 6,000, 8,000, and 10,000 AU Duration : 6 weeks

Dose : 1,000, 2,000,

This was a DBPC

trial during the first year. After completing

12 months of

treatment, subjects

previously treated

with placebo were

switched to active SCIT for 2

additional years,

and then AIT was discontinued. A subjective

evaluation was

conducted 4 years

phase) 2 years

Study description:

characteristics Allergen Parietaria

judaica and

Parietaria

officinalis

Tests: Positive sIgE level and SPT response to Parietaria species

Patients’

Diagnosis: ARC with single sensitization to Parietaria species

Asthma: 20% mild asthma

13 12 Age: 13-62 years

country SCIT Placebo

TABLE E2 . (Continued)

Ariano et al, 28

1999, Italy

Author, year,

171